SG Americas Securities LLC Reduces Holdings in Denali Therapeutics Inc. $DNLI

SG Americas Securities LLC trimmed its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 68.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 46,642 shares of the company’s stock after selling 102,950 shares during the quarter. SG Americas Securities LLC’s holdings in Denali Therapeutics were worth $896,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of DNLI. Foresite Capital Management VI LLC purchased a new position in shares of Denali Therapeutics during the third quarter valued at approximately $14,520,000. Capricorn Fund Managers Ltd purchased a new stake in Denali Therapeutics in the fourth quarter worth $1,027,000. Holocene Advisors LP lifted its stake in Denali Therapeutics by 677.8% in the third quarter. Holocene Advisors LP now owns 3,135,712 shares of the company’s stock worth $45,531,000 after acquiring an additional 2,732,540 shares during the period. Baillie Gifford & Co. boosted its holdings in Denali Therapeutics by 6.2% in the fourth quarter. Baillie Gifford & Co. now owns 12,310,889 shares of the company’s stock valued at $203,253,000 after acquiring an additional 719,304 shares in the last quarter. Finally, Boxer Capital Management LLC purchased a new position in Denali Therapeutics during the 3rd quarter valued at $3,630,000. 92.92% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. The Goldman Sachs Group upped their price objective on shares of Denali Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. HC Wainwright increased their price target on shares of Denali Therapeutics from $32.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Robert W. Baird raised their price objective on shares of Denali Therapeutics from $32.00 to $34.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Wall Street Zen upgraded Denali Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Wedbush decreased their target price on Denali Therapeutics from $25.00 to $23.00 and set an “outperform” rating for the company in a research report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $34.25.

Denali Therapeutics Price Performance

DNLI stock opened at $25.83 on Monday. The business has a 50 day moving average of $21.12 and a 200 day moving average of $20.05. The firm has a market cap of $4.10 billion, a PE ratio of -8.97 and a beta of 0.96. Denali Therapeutics Inc. has a twelve month low of $12.58 and a twelve month high of $26.80. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Thursday, May 7th. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.04. During the same period in the prior year, the company earned ($0.78) earnings per share. On average, research analysts forecast that Denali Therapeutics Inc. will post -2.77 EPS for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.